WASHINGTON, D.C.—A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms of cardiovascular disease, demonstrated that replacing ...
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...
Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...
Zacks Investment Research on MSN
Should you continue to hold EW stock in your portfolio?
Edwards Lifesciences Corporation EW is well-poised to grow in the coming quarters owing to its Surgical Structural Heart, which pioneered the RESILIA tissue. The company’s Transcatheter Aortic Valve ...
Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...
Reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10% Advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025: TAVR growth ...
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Edwards Lifesciences provides ...
SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback